# US 2017/0283475 A1 · Cancer vaccine compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283475 A1
- Document ID: US20170283475A1
- Status: Published application
- Kind: A1
- Application number: 15/327,225
- Filed: 2015-07-17
- Published: 2017-10-05
- Earliest claimed: 2014-07-18
- Assignees: University of Washington
- Applicants: University of Washington
- Inventors: Mary L. DISIS; Elizabeth BROUSSARD
- Web page: https://patentgrep.com/patent/US20170283475A1

## CPC

- C07K 14/47: from mammals
- A61K 39/0011: {Cancer antigens}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/71: for growth factors; for growth regulators
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C07K 14/82: Translation products from oncogenes
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 15/09: Recombinant DNA-technology
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present application describes compositions that include an epitope of a peptide that elicits an immune response in a subject following administration. The compositions described herein include nucleic acids. The present application also describes compositions that include peptides. Also described herein are methods that include administering a composition comprising an epitope of a peptide to a subject in need thereof.

## Claims

### Claim at position 1

1-82. (canceled)

### Claim 83

A composition comprising an isolated and purified plasmid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises a plurality of sequences each comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-22 and 27-45.

### Claim 84 (depends on 83)

The composition of claim 83, wherein the plurality of sequences further comprises a sequence comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 23-26.

### Claim 85 (depends on 83)

The composition of claim 83, wherein the plurality of sequences each comprise at least 90% sequence identity to at least 8 contiguous amino acids from a sequence selected from SEQ ID NOs: 1-22 and 27-45.

### Claim 86 (depends on 84)

The composition of claim 84, wherein the plurality of sequences further comprises the sequence comprising at least 90% sequence identity to at least 8 contiguous amino acids from a sequence selected from SEQ ID NOs: 1-45.

### Claim 87 (depends on 83)

The composition of claim 83, wherein the plurality of sequences are contiguous.

### Claim 88 (depends on 84)

The composition of claim 84, wherein the plurality of sequences are contiguous.

### Claim 89 (depends on 87)

The composition of claim 87, wherein the contiguous sequence further comprises a linker between two or more sequences of the plurality of sequences.

### Claim 90 (depends on 88)

The composition of claim 88, wherein the contiguous sequence further comprises a linker between two or more sequences of the plurality of sequences.

### Claim 91 (depends on 83)

The composition of claim 83, wherein the plurality of sequences comprises a first sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 1-22 and 27-45, and a second sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 1-22 and 27-45, wherein the first sequence and the second sequence are different sequences.

### Claim 92 (depends on 83)

The composition of claim 83, wherein the plurality of sequences comprises a first sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 1-2, a second sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 3-10, and a third sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 27-31.

### Claim 93 (depends on 84)

The composition of claim 84, wherein the plurality of sequences comprises a first sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 1-22 and 27-45, and a second sequence selected from the sequences consisting at least 90% sequence identity of SEQ ID NOs: 1-45, wherein the first sequence and the second sequence are different sequences.

### Claim 94 (depends on 83)

The composition of claim 83 further comprising an excipient.

### Claim 95

A composition comprising:
a) a first isolated and purified plasmid comprising a first nucleotide sequence encoding a first polypeptide, wherein the first polypeptide comprises at least one sequence comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-45, and
b) a second isolated and purified plasmid comprising a second nucleotide sequence encoding a second polypeptide, wherein the second polypeptide comprises at least one sequence comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-22 and 27-45;
wherein the at least one sequence of the first polypeptide is different than the at least one sequence of the second polypeptide.

### Claim 96 (depends on 95)

The composition of claim 95, wherein the at least one sequence of the first polypeptide comprises at least 90% sequence identity to at least 8 contiguous amino acids from a sequence selected from SEQ ID NOs: 1-45.

### Claim 97 (depends on 95)

The composition of claim 95, wherein the at least one sequence of the second polypeptide comprises at least 90% sequence identity to at least 8 contiguous amino acids from a sequence selected from SEQ ID NOs: 1-22 and 27-45.

### Claim 98 (depends on 95)

The composition of claim 95, wherein the at least one additional sequence of the first polypeptide comprises a first plurality of sequences each comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-45.

### Claim 99 (depends on 95)

The composition of claim 95, wherein the at least one additional sequence of the second polypeptide comprises a second plurality of sequences each comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-22 and 27-45.

### Claim 100 (depends on 98)

The composition of claim 98, wherein the first plurality of sequences are contiguous.

### Claim 101 (depends on 99)

The composition of claim 99, wherein the second plurality of sequences are contiguous.

### Claim 102 (depends on 100)

The composition of claim 100, wherein the contiguous sequence further comprises a linker between two or more sequences of the first plurality of sequences.

### Claim 103 (depends on 101)

The composition of claim 101, wherein the contiguous sequence further comprises a linker between two or more sequences of the second plurality of sequences.

### Claim 104 (depends on 95)

The composition of claim 95, wherein the at least one sequence of the first polypeptide comprises a first sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 1-2, a second sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 3-10, and a third sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 27-31.

### Claim 105 (depends on 95)

The composition of claim 95, wherein the at least one sequence of the second polypeptide comprises a first sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 1-2, a second sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 3-10, and a third sequence selected from the sequences consisting of at least 90% sequence identity to SEQ ID NOs: 27-30.

### Claim 106 (depends on 95)

The composition of claim 95, further comprising an excipient.

### Claim 107

A method of treating a subject in need thereof, the method comprising administering to the subject in need thereof an isolated and purified plasmid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises a plurality of sequences each comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-22 and 27-45.

### Claim 108 (depends on 107)

The method of claim 107, wherein the polypeptide further comprises a sequence comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 23-26.